GlassScriptPhysician profile
Kiran Malik
NPI 1568816999
$2,930.59
in general payments reported to CMS, 2019-2025
25 companies · $762 in 2025
The $762 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.74 · 2020: $140 · 2021: $153 · 2022: $303 · 2023: $968 · 2024: $556 · 2025: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,285.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $739.75 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $429.83 | 2021-2025 | |
| Pfizer INC. | $423.48 | 2023-2025 | |
| Lilly USA, LLC | $255.79 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $220.18 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $179.19 | 2020-2024 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.92 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $106.07 | 2020-2025 | Trelegy Ellipta |
| Abbott Laboratories | $91.64 | 2022-2024 | Freestyle Libre 3, Proclaim |
| Medtronic, INC. | $45.04 | 2022 | |
| Stryker Corporation | $37.69 | 2025 | Clottriever Bold Catheter |
| Biohaven Pharmaceutical Holding Company LTD. | $35.00 | 2022 | |
| Merck Sharp & Dohme LLC | $31.69 | 2019-2023 | Dificid |
| Cranial Technologies, INC | $31.40 | 2021-2023 | Doc Band |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.34 | 2022-2024 | Xifaxan |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $23.56 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $19.26 | 2022 | |
| Grifols USA, LLC | $19.03 | 2022 | |
| Phadia US INC. | $18.18 | 2024 | Immunocap |
| Esperion Therapeutics, INC. | $16.37 | 2022 | |
| Dexcom, INC. | $16.30 | 2023 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $14.00 | 2021 | |
| Amarin Pharma, INC. | $12.66 | 2020 | |
| Ironwood Pharmaceuticals, INC | $12.28 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kiran Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.